Integrated LC–MS/MS bioanalysis for the simultaneous quantification of metformin HCl, pioglitazone HCl, and teneligliptin HBr hydrate in human plasma

0 This is a summary report of the conference on "Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies." The conference was held from December 3 to 5,1990, in the Washington, D.C., area and was sponsored by the American Association of Pharmaceutical Scientists, the US. Food and Drug Administration, Federation International Pharmaceutique, Health Protection Branch (Canada), and the Association of Official Analytical Chemists. The report presents our assessment of the major agreements and issues discussed at the conference. The report is also intended to provide guiding principles for validation of analytical methods used in bioavailability, bioequivalence, and pharmacokinetics studies in humans and animals. The objectives of the conference were as follows: (1) to reach a consensus on what should be required in analytical methods validation and the procedures to establish validation; (2) to determine processes of application of the validation procedures in bioavailability, bioequivalence, and pharmacokinetics studies; and (3) to develop a report on analytical methods validation that may be referred to in developing future formal guidelines. Acceptable standards for documenting and validating analytical methods with regard to processes, parameters, or data treatments are discussed because of their importance in assessing pharmacokinetic, bioavailability, and bioequivalence studies. Other topics that were considered essential in the conduct of pharmacokinetic studies or in establishing bioequivalency criteria, including measurement of drug metabolites and stereoselective determinations, are also discussed. ___ -. ~. ~ _ _ Analytical methods that are used for the quantitative determination of drugs and their metabolites in biological samples play a significant role in evaluation and interpretation of bioavailability, bioequivalence, and pharmacokinetic data. It is essential to use well-characterized and fully validated analytical methods to yield reliable results that can be satisfactorily interpreted. Analytical methods and techniques are constantly being changed and improved; in many instances, these methods are at the cutting edge of the technology. It is also important to emphasize that each analytical technique has its own characteristics, which will vary from drug to drug. Moreover, the appropriateness of the technique may be influenced by the ultimate objective of the study. Specific validation criteria are needed for methods intended for analysis of each analyte (drug and/or metabolite). Although validation of each method will be independent of those of other methods, there may be situations in which comparison of the methods will be necessary (e.g., when more than one method has been used in a long-term study). When sample analysis is conducted at more than one site, it is necessary to validate the analytical methodb) at each site and provide appropriate validation information for different sites to establish interlaboratory reliability. Unless a method is used on a regular basis, providing confidence in its continued validity, it is essential to document that the method is still valid before analysis of samples in the study. Adequate validation for methods not used on a regular basis often consists of running a standard curve with new quality-control samples to show that the responses, relationship, and general characteristics of the method are similar to previous valida-

Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies

This is a summary report of the conference on Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies. The conference was held from December 3 to 5, 1990 in the Washington, DC area and was sponsored by the American Association of Pharmaceutical Scientists, US Food and Drug Administration, Federation International Pharmaceutique, Health Protection Branch (Canada) and Association of Official Analytical Chemists. The purpose of the report is to represent our assessment of the major agreements and issues discussed at the conference. The report is also intended to provide guiding principles for validation of analytical methods employed in bioavailability, bioequivalence and pharmacokinetic studies in man and animals. The objectives of the conference were: 1. To reach a consensus on what should be required in analytical methods validation and the procedures to establish validation; 2. To determine processes of application of the validation procedures in the bioavailability, bioequivalence and pharmacokinetic studies; 3. To develop a report on analytical methods validation (which may be referred to in developing future formal guidelines). Acceptable standards for documenting and validating analytical methods with regard to processes, parameters or data treatments were discussed because of their importance in assessment of pharmacokinetic, bioavailability and bioequivalence studies. Other topics which were considered essential in the conduct of pharmacokinetic studies or in establishing bioequivalency criteria, including measurement of drug metabolites and stereoselective determinations, were also deliberated.

Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies: Sponsored by the American Association of Pharmaceutical Chemists, U.S. Food and Drug Administration, Fédération Internationale Pharmaceutique, Health Protection Branch (Canada) and Association of Official Analytical Chemists

A sensitive validated liquid chromatography-tandem mass spectrometric method (LC-MS/MS) for gabapentin (GB) in human plasma has been developed and applied to pharmacokinetic (PK) and bioequivalence (BE) studies in human. In a randomized crossover design with a 1-week period, each subject received a 300 mg GB capsule. The procedure involves a simple protein precipitation with acetonitrile and separated by LC with a Gemini C(18) column using acetonitrile-10 mm ammonium acetate (20:80, v/v, pH 3.2) as mobile phase. The GB and internal standard [(S)-(+)-alpha-aminocyclohexanepropionic acid hydrate] were analyzed using an LC-API 2000 MS/MS in multiple reaction monitoring mode. The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 172.0 --> 154.0 and m/z 172.0 --> 126.0 for GB and IS, respectively. The assay exhibited good linearity over a working range of 20-5000 ng/mL for GB in human plasma with a lower limit of quantitation of 20 ng/mL. No endogenous compounds were found to interfere with the analysis. The accuracy and precision were shown for concentrations over the standard ranges. This method was successfully applied for the PK and BE studies by analysis of blood samples taken up to 36 h after an oral dose of 300 mg of GB in 24 healthy volunteers.

A LC-MS/MS method has been developed for the estimation of rosuvastatin in human plasma using atorvastatin as internal standard. Rosuvastatin is a lipid-lowering drug prescribed for the treatment of hyper-cholestrolemia and dyslipidimia. Solid phase extraction (SPE) was used for the purification and pre-concentration of analyte from human plasma matrix. The chromatographic separation was achieved within 6.0 min by an isocratic mobile phase containing 0.2% formic acid in water and acetonitrile (40: 60, v/v), flowing through YMC J' Sphere ODS H-80, 150 x 4.6 mm, 4.0 µm analytical column, at a flow rate of 1.0 mL min-1 with split of 200 µL to mass spectrometer and 800 µL to waste. Multiple reaction monitoring (MRM) transitions were measured in the positive mode at m/z 482 and 258 for rosuvastatin and m/z 559 and 440 for internal standard respectively. A detailed validation of the method was performed as per USFDA guidelines and the standard curves were found to be linear in the range 1.0 ng mL-1 to 50.0 ng mL-1 with the mean correlation coefficient more than 0.99. The absolute recovery was more than 50.14% for rosuvastatin and 54.65% for internal standard. In human plasma, rosuvastatin was stable for 138 days at -70 ± 5 °C and for 24 hours at ambient temperature. After extraction from plasma, the reconstituted samples of rosuvastatin were stable in auto sampler at 10 °C for 8 hours. Upon subjecting to three freeze thaw cycles, there was no change in the recovery of the analyte. The method was simple, specific, sensitive, precise, accurate and suitable for bioequivalence and pharmacokinetic studies. It was successfully applied to the pilot bioequivalence study of rosuvastatin 20 mg tablets of M/s Zydus Cadila health care Ltd. India versus 20 mg Crestor tablet of M/s Astra Zeneca, USA; in male human subjects.

Development and validation of a LC–MS quantification method for the lantibiotic MU1140 in rat plasma

Validation of a sensitive simultaneous LC-MS/MS method for the quantification of novel anti-cancer thiazolidinedione and quinazolin-4-one derivatives in rat plasma and its application in a rat pharmacokinetic study

Background and Aim: The current study attempted to invent and evaluate an easy and sensitive Stability indicating UV spectrophotometric method for simultaneous determination of Glimepiride and Pioglitazone HCl. Material and Methods: To provide a simple, sensitive, robust, precise, and accurate Stability indicating UV-Spectrophotometric method for the simultaneous estimate of Glimepiride and Pioglitazone HCl, as well as to develop a combined tablet dosage formulation of Glimepiride and Pioglitazone HCl. The best conditions for drug analysis were found using Methanol as the solvent. Results and Discussion: Glimepiride and Pioglitazone Hydrochloride had maximum absorption wavelengths of 227.6nm and 266.8nm, respectively. Glimepiride and Pioglitazone Hydrochloride demonstrated linear responses between concentration ranges of 2-12g/ml and 5-30g/ml, respectively. It was discovered that the linear regression coefficient was 0.999. According to ICH criteria, the method was validated for sensitivity, specificity, range and linearity, precision, and ruggedness, all validation results were found to be within acceptable limits. Glimepiride and pioglitazone HCl were exposed to forced degradation under ICH guidelines. The resulting samples were used for deterioration experiments utilizing the established procedure. Conclusion: As a result, it may be argued that the procedure was novel, straightforward, precise, specific, and selective for the simultaneous estimation of Glimepiride and Pioglitazone HCl in bulk Drugs.

A novel High Performance Liquid Chromatography-electrospray mass spectrometric method has been developed for the estimation of Ursodiol (Ursodeoxycholic acid)--a bile acid, in human plasma using Ornidazole as internal standard. The methodology involved solid phase extraction of the analyte from human plasma matrix. The chromatographic separation was achieved within seven minutes by an isocratic mobile phase containing 1.0 mM ammonium acetate and Acetonitrile (65:35, v/v), flowing through XTerra MS C18, 100 x 2.1, 3.5 microm analytical column, at a flow rate of 0.2 ml/min. Ion signals were measured in negative mode for Ursodiol and internal standard at m/z 391.3 and 278.1, respectively. A detailed validation of the method was performed as per USFDA guidelines and the standard curves were found to be linear in the range 50.0 ng/ml to 3000.0 ng/ml with the mean correlation coefficient more than 0.99. The absolute recovery was more than 54.90% for Ursodiol and 76.51% for internal standard. Ursodiol was stable for sixty-nine days at -70 degrees C and for eight hours at ambient temperature. After extraction from plasma, the reconstituted samples of Ursodiol were stable in autosampler at 10 degrees C for forty-eight hours. Upon subjecting to three freeze thaw cycles, there was no change in the recovery of the analyte. The integrity of the plasma samples remained unaffected even upon four-fold dilution with drug free human plasma. The method was simple, specific, sensitive, precise, accurate and suitable for bioequivalence and pharmacokinetic studies. It was successfully applied to the pilot bioequivalence study of Ursodiol in male human subjects.

Determination of visnagin in rat plasma by liquid chromatography with tandem mass spectrometry and its application to in vivo pharmacokinetic studies

Application of a high performance liquid chromatography–tandem mass spectrometry method for determination of buflomedil in human plasma for a bioequivalence study

Quantification of sibutramine and its two metabolites in human plasma by LC–ESI-MS/MS and its application in a bioequivalence study

Decision Science for Generic Drug Development and Review.

Direct injection, column switching–liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study